HIV accessory proteins versus host restriction factors

Walker, 2012, The T-cell response to HIV, Cold Spring Harb Perspect Med, 2 Perreau, 2013, Immune response to HIV, Curr Opin HIV AIDS, 8, 333 Strebel, 2009, Human cellular restriction factors that target HIV-1 replication, BMC Med, 7, 48, 10.1186/1741-7015-7-48 Laguette, 2011, SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx, Nature, 474, 654, 10.1038/nature10117 Hrecka, 2011, Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein, Nature, 474, 658, 10.1038/nature10195 Beer, 1998, Simian immunodeficiency virus of African green monkeys is apathogenic in the newborn natural host, J Acquir Immune Defic Syndr Hum Retrovirol, 18, 210, 10.1097/00042560-199807010-00003 Gao, 1999, Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes, Nature, 397, 436, 10.1038/17130 Bozek, 2010, Positive selection of HIV host factors and the evolution of lentivirus genes, BMC Evol Biol, 10, 186, 10.1186/1471-2148-10-186 Sheehy, 2002, Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein, Nature, 418, 646, 10.1038/nature00939 Goila-Gaur, 2008, HIV-1 Vif, APOBEC, and intrinsic immunity, Retrovirology, 5, 51, 10.1186/1742-4690-5-51 Harris, 2004, Retroviral restriction by APOBEC proteins, Nat Rev Immunol, 4, 868, 10.1038/nri1489 Mohammed, 2012, SAR and lead optimization of an HIV-1 Vif-APOBEC3G axis inhibitor, ACS Med Chem Lett, 3, 465, 10.1021/ml300037k Zuo, 2012, Small-molecule inhibition of human immunodeficiency virus type 1 replication by targeting the interaction between Vif and ElonginC, J Virol, 86, 5497, 10.1128/JVI.06957-11 Walker, 2010, Identification of dominant negative human immunodeficiency virus type 1 Vif mutants that interfere with the functional inactivation of APOBEC3G by virus-encoded Vif, J Virol, 84, 5201, 10.1128/JVI.02318-09 Mulder, 2008, Cytidine deamination induced HIV-1 drug resistance, Proc Natl Acad Sci U S A, 105, 5501, 10.1073/pnas.0710190105 Wissing, 2010, HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors, Mol Aspects Med, 31, 383, 10.1016/j.mam.2010.06.001 Opi, 2007, Human immunodeficiency virus type 1 Vif inhibits packaging and antiviral activity of a degradation-resistant APOBEC3G variant, J Virol, 81, 8236, 10.1128/JVI.02694-06 Goila-Gaur, 2009, Differential sensitivity of “old” versus “new” APOBEC3G to human immunodeficiency virus type 1 vif, J Virol, 83, 1156, 10.1128/JVI.01734-08 Miyagi, 2008, APOBEC3G-independent reduction in virion infectivity during long-term HIV-1 replication in terminally differentiated macrophages, Virology, 379, 266, 10.1016/j.virol.2008.06.033 Zhang, 2012, T-cell differentiation factor CBF-beta regulates HIV-1 Vif-mediated evasion of host restriction, Nature, 481, 376, 10.1038/nature10718 Jager, 2012, Vif hijacks CBF-beta to degrade APOBEC3G and promote HIV-1 infection, Nature, 481, 371, 10.1038/nature10693 Speck, 2002, Core-binding factors in haematopoiesis and leukaemia, Nat Rev Cancer, 2, 502, 10.1038/nrc840 Kim, 2013, CBFβ stabilizes HIV Vif to counteract APOBEC3 at the expense of RUNX1 target gene expression, Mol Cell, 49, 632, 10.1016/j.molcel.2012.12.012 Andrew, 2010, HIV-1 Vpu targets cell surface markers CD4 and BST-2 through distinct mechanisms, Mol Aspects Med, 31, 407, 10.1016/j.mam.2010.08.002 Neil, 2008, Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu, Nature, 451, 425, 10.1038/nature06553 Van Damme, 2008, The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein, Cell Host Microbe, 3, 245, 10.1016/j.chom.2008.03.001 Schubert, 1996, Identification of an ion channel activity of the Vpu transmembrane domain and its involvement in the regulation of virus release from HIV-1-infected cells, FEBS Lett, 398, 12, 10.1016/S0014-5793(96)01146-5 Ewart, 1996, The Vpu protein of human immunodeficiency virus type 1 forms cation-selective ion channels, J Virol, 70, 7108, 10.1128/JVI.70.10.7108-7115.1996 Hsu, 2004, Mutual functional destruction of HIV-1 Vpu and host TASK-1 channel, Mol Cell, 14, 259, 10.1016/S1097-2765(04)00183-2 Akari, 2001, The human immunodeficiency virus type 1 accessory protein Vpu induces apoptosis by suppressing the nuclear factor kappaB-dependent expression of antiapoptotic factors, J Exp Med, 194, 1299, 10.1084/jem.194.9.1299 Kupzig, 2003, Bst-2/HM1.24 is a raft-associated apical membrane protein with an unusual topology, Traffic, 4, 694, 10.1034/j.1600-0854.2003.00129.x Andrew, 2011, C-terminal hydrophobic region in human bone marrow stromal cell antigen 2 (BST-2)/tetherin protein functions as second transmembrane motif, J Biol Chem, 286, 39967, 10.1074/jbc.M111.287011 Andrew, 2009, The formation of cysteine-linked dimers of BST-2/tetherin is important for inhibition of HIV-1 virus release but not for sensitivity to Vpu, Retrovirology, 6, 80, 10.1186/1742-4690-6-80 Perez-Caballero, 2009, Tetherin inhibits HIV-1 release by directly tethering virions to cells, Cell, 139, 499, 10.1016/j.cell.2009.08.039 Andrew, 2012, The size and conservation of a coiled-coil structure in the ectodomain of human BST-2/tetherin is dispensable for inhibition of HIV-1 virion release, J Biol Chem, 287, 44278, 10.1074/jbc.M112.418822 Miyagi, 2009, Vpu enhances HIV-1 virus release in the absence of Bst-2 cell surface down-modulation and intracellular depletion, Proc Natl Acad Sci U S A, 106, 2868, 10.1073/pnas.0813223106 Dube, 2011, HIV-1 Vpu antagonizes BST-2 by interfering mainly with the trafficking of newly synthesized BST-2 to the cell surface, Traffic, 12, 1714, 10.1111/j.1600-0854.2011.01277.x Sauter, 2012, Human tetherin exerts strong selection pressure on the HIV-1 group N Vpu protein, PLoS Pathog, 8 Shingai, 2011, Some human immunodeficiency virus type 1 vpu proteins are able to antagonize macaque BST-2 in vitro and in vivo: Vpu-negative simian-human immunodeficiency viruses are attenuated in vivo, J Virol, 85, 9708, 10.1128/JVI.00626-11 Bour, 1996, The human immunodeficiency virus (HIV) type 2 envelope protein is a functional complement to HIV type 1 Vpu that enhances particle release of heterologous retroviruses, J Virol, 70, 8285, 10.1128/JVI.70.12.8285-8300.1996 Hauser, 2010, HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment, Retrovirology, 7, 51, 10.1186/1742-4690-7-51 Schubert, 1999, Regulation of virus release by the macrophage-tropic human immunodeficiency virus type 1 AD8 isolate is redundant and can be controlled by either Vpu or Env, J Virol, 73, 887, 10.1128/JVI.73.2.887-896.1999 Sauter, 2009, Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains, Cell Host Microbe, 6, 409, 10.1016/j.chom.2009.10.004 Nikovics, 2012, Counteraction of tetherin antiviral activity by two closely related SIVs differing by the presence of a Vpu gene, PLoS ONE, 7 Liberatore, 2011, Tetherin is a key effector of the antiretroviral activity of type I interferon in vitro and in vivo, Proc Natl Acad Sci U S A, 108, 18097, 10.1073/pnas.1113694108 Casartelli, 2010, Tetherin restricts productive HIV-1 cell-to-cell transmission, PLoS Pathog, 6, e1000955, 10.1371/journal.ppat.1000955 Strebel, 1988, A novel gene of HIV-1, vpu, and its 16-kilodalton product, Science, 241, 1221, 10.1126/science.3261888 Terwilliger, 1989, Functional role of human immunodeficiency virus type 1 vpu, Proc Natl Acad Sci U S A, 86, 5163, 10.1073/pnas.86.13.5163 Cohen, 1988, Identification of a protein encoded by the vpu gene of HIV-1, Nature, 334, 532, 10.1038/334532a0 Theodore, 1996, Construction and characterization of a stable full-length macrophage-tropic HIV type 1 molecular clone that directs the production of high titers of progeny virions, AIDS Res Hum Retroviruses, 12, 191, 10.1089/aid.1996.12.191 Bour, 2003, Naturally occurring amino acid substitutions in the HIV-2 ROD envelope glycoprotein regulate its ability to augment viral particle release, Virology, 309, 85, 10.1016/S0042-6822(02)00128-9 Tristem, 1990, Origin of vpx in lentiviruses, Nature, 347, 341, 10.1038/347341b0 Planelles, 2010, Roles of Vpr and Vpx in modulating the virus-host cell relationship, Mol Aspects Med, 31, 398, 10.1016/j.mam.2010.05.002 Fujita, 2010, Multifaceted activity of HIV Vpr/Vpx proteins: the current view of their virological functions, Rev Med Virol, 20, 68, 10.1002/rmv.636 Srivastava, 2008, Lentiviral Vpx accessory factor targets VprBP/DCAF1 substrate adaptor for cullin 4 E3 ubiquitin ligase to enable macrophage infection, PLoS Pathog, 4, e1000059, 10.1371/journal.ppat.1000059 Goujon, 2009, The Vpx protein of HIV-2, Virologie, 13, 259 Berger, 2011, SAMHD1-deficient CD14+ cells from individuals with Aicardi-Goutieres syndrome are highly susceptible to HIV-1 infection, PLoS Pathog, 7, e1002425, 10.1371/journal.ppat.1002425 Goujon, 2008, Characterization of simian immunodeficiency virus SIVSM/human immunodeficiency virus type 2 Vpx function in human myeloid cells, J Virol, 82, 12335, 10.1128/JVI.01181-08 Goujon, 2007, SIVSM/HIV-2 Vpx proteins promote retroviral escape from a proteasome-dependent restriction pathway present in human dendritic cells, Retrovirology, 4, 2, 10.1186/1742-4690-4-2 Sharova, 2008, Primate lentiviral Vpx commandeers DDB1 to counteract a macrophage restriction, PLoS Pathog, 4, e1000057, 10.1371/journal.ppat.1000057 Gramberg, 2010, Evidence for an activation domain at the amino terminus of simian immunodeficiency virus Vpx, J Virol, 84, 1387, 10.1128/JVI.01437-09 Baldauf, 2012, SAMHD1 restricts HIV-1 infection in resting CD4(+) T cells, Nat Med, 18, 1682, 10.1038/nm.2964 Descours, 2012, SAMHD1 restricts HIV-1 reverse transcription in quiescent CD4+ T-cells, Retrovirology, 9, 87, 10.1186/1742-4690-9-87 Ahn, 2012, HIV/simian immunodeficiency virus (SIV) accessory virulence factor Vpx loads the host cell restriction factor SAMHD1 onto the E3 ubiquitin ligase complex CRL4DCAF1, J Biol Chem, 287, 12550, 10.1074/jbc.M112.340711 Welbourn, 2012, Identification and characterization of naturally occurring splice variants of SAMHD1, Retrovirology, 9, 86, 10.1186/1742-4690-9-86 White, 2013, Contribution of SAM and HD domains to retroviral restriction mediated by human SAMHD1, Virology, 436, 81, 10.1016/j.virol.2012.10.029 Goncalves, 2012, SAMHD1 is a nucleic-acid binding protein that is mislocalized due to Aicardi-Goutieres syndrome-associated mutations, Hum Mutat, 33, 1116, 10.1002/humu.22087 Beloglazova, 2013, Nuclease activity of the human SAMHD1 protein implicated in the Aicardi-Goutieres syndrome and HIV-1 restriction, J Biol Chem, 288, 8101, 10.1074/jbc.M112.431148 Goldstone, 2011, HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase, Nature, 480, 379, 10.1038/nature10623 Powell, 2011, Aicardi-Goutieres syndrome gene and HIV-1 restriction factor SAMHD1 is a dGTP-regulated deoxynucleotide triphosphohydrolase, J Biol Chem, 286, 43596, 10.1074/jbc.C111.317628 Lahouassa, 2012, SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates, Nat Immunol, 13, 223, 10.1038/ni.2236 Kim, 2012, Tight interplay among SAMHD1 protein level, cellular dNTP levels, and HIV-1 proviral DNA synthesis kinetics in human primary monocyte-derived macrophages, J Biol Chem, 287, 21570, 10.1074/jbc.C112.374843 St Gelais, 2012, SAMHD1 restricts HIV-1 infection in dendritic cells (DCs) by dNTP depletion, but its expression in DCs and primary CD4+ T-lymphocytes cannot be upregulated by interferons, Retrovirology, 9, 105, 10.1186/1742-4690-9-105 White, 2013, The retroviral restriction ability of SAMHD1, but not its deoxynucleotide triphosphohydrolase activity, is regulated by phosphorylation, Cell Host Microbe, 13, 441, 10.1016/j.chom.2013.03.005 Cribier, 2013, Phosphorylation of SAMHD1 by cyclin A2/CDK1 regulates its restriction activity toward HIV-1, Cell Rep, 3, 1036, 10.1016/j.celrep.2013.03.017 Endicott, 1999, Cyclin-dependent kinases: inhibition and substrate recognition, Curr Opin Struct Biol, 9, 738, 10.1016/S0959-440X(99)00038-X Nigg, 1993, Cellular substrates of p34(cdc2) and its companion cyclin-dependent kinases, Trends Cell Biol, 3, 296, 10.1016/0962-8924(93)90011-O Landi, 2011, One protein to rule them all: modulation of cell surface receptors and molecules by HIV Nef, Curr HIV Res, 9, 496, 10.2174/157016211798842116 Doria, 2011, Role of the CD4 down-modulation activity of Nef in HIV-1 infectivity, Curr HIV Res, 9, 490, 10.2174/157016211798842125 Abraham, 2012, HIV-1 Nef: a multifaceted modulator of T cell receptor signaling, Cell Commun Signal, 10, 39, 10.1186/1478-811X-10-39 Romani, 2012, Lentivirus Vpr and Vpx accessory proteins usurp the cullin4-DDB1 (DCAF1) E3 ubiquitin ligase, Curr Opin Virol, 2, 755, 10.1016/j.coviro.2012.09.010 Welbourn, 2013, Restriction of virus infection but not catalytic dNTPase activity are regulated by phosphorylation of SAMHD1, J Virol, 87, 11516, 10.1128/JVI.01642-13